Studies from women with recurrent vulvovaginal candidiasis (RVVC) and from an animal model of experimental vaginitis suggest that deficiencies in immune function should be examined at the local rather than systemic level. Evidence of vaginal cell-mediated immunity (CMI) was evaluated for the first time in cervicovaginal lavage (CVL) fluid from RVVC patients. Results showed that although constitutive Th1-and Th2-type cytokine expression was detectable in CVL fluid from normal women, and differences in cytokines were observed in RVVC patients, limitations in experimental design of such de novo analyses urged caution in interpretation. Alternatively, attempts were made to establish conditions in control subjects whereby vaginal immunity could be detected after intravaginal challenge with Candida antigen. Preliminary results showed that Th1-type cytokines (interleukin-2 and -12, interferon-g) and histamine were increased 16 -18 h after intravaginal introduction of Candida skin test antigen. Intravaginal antigenic challenge represents a novel approach for studying Candida-specific vaginal CMI.
Recurrent vulvovaginal candidiasis (RVVC) is an opportu-
phocyte (PBL) proliferation have been reported [7, 8, 10 -12] . Similarly, comprehensive studies involving extensive cytokine nistic mucosal infection caused by Candida albicans that affects up to 5% of otherwise healthy women of child-bearing analyses of RVVC patients during both symptomatic episodes age [1] . Although antimycotic resistance does not appear to and asymptomatic periods of remission, including longitudinal play a major role in recurrence [2] , women with RVVC usually analyses, showed that PBL from women with RVVC had norexperience repeat episodes shortly after successful therapeutic mal Th1-type cytokine expression in response to Candida antiintervention [1] . While several exogenous factors (antibiotics gens [8] , which is characteristic of protective immune reactivity and oral contraceptives) predispose some women to acute VVC to C. albicans [13, 14] . [1] , the underlying factors contributing to RVVC are largely
Results from an estrogen-dependent animal model of experiunknown. Because of the high incidence of mucosal candidiasis mental vaginal candidiasis have paralleled these clinical obserin patients with reduced cell-mediated immunity (CMI), such as vations. Results indicate that although a localized vaginal C. those with AIDS [3, 4] , transplantation [5] , and corticosteroid albicans infection stimulates Candida-specific systemic Th1-therapy [6] , it is postulated that deficiencies in CMI also play type CMI [15, 16] , preinduced Candida-specific systemic CMI a significant role in the etiology of RVVC.
was not protective against vaginal candidiasis [17] . In contrast, Studies examining systemic CMI in peripheral blood of however, mice given a spontaneously resolving primary vaginal women with RVVC have thus far failed to show a deficiency infection in the absence of estrogen were partially protected or distinct pattern of reduced activity [7 -9] , although reduced from a second vaginal infection under pseudoestrus conditions Candida-specific skin test reactivity and peripheral blood lym- [18] . In these experiments, inhibition of Candida-specific systemic CMI had no effect on this protection, suggesting the presence of a locally acquired mucosal immune response [18] . Similarly, the depletion of systemic CD4 and CD8 T cells with ate hypersensitivity. Although a paucity of information exists for CMI at the cervicovaginal level, the vaginal mucosa appears PBL from each patient and control subject were cultured in vitro to contain all of the necessary components to elicit competent for lymphoproliferation and cytokine production in response to a CMI, including class II major histocompatibility complex cells mitogen, soluble and particulate Candida antigens, and a bacterial and T lymphocytes [24, 25] . In fact, these cells may be uniquely
antigen.
compartmentalized, as we [26] and others [27, 28] The results were compared with cytokines produced by the served as the bacterial antigen.
patient PBL in response to Candida antigens in vitro and to
Proliferation assays. Proliferation assays were used as a genlocal and PBL-mediated cytokines in normal healthy women eral measure of lymphocyte activity to Candida antigens. PHA without a history of vaginal candidiasis.
was included as a quality control for positive lymphocyte responses. The methods used in our laboratory for proliferation assays with PBL have been described previously [8] . Briefly, 1.5 and incubated for an additional 6 h. The contents of the wells were School of Medicine. Patients were further classified at testing into harvested onto glass fiber filters, and the radioactivity incorporated the culture-positive RVVC group (n Å 16), defined as those with into the cells was counted in a liquid scintillation counter (Becka symptomatic episode of recurrent C. albicans vaginitis, and the man Instruments, Irvine, CA). Data were expressed as proliferation culture-negative RVVC group (n Å 18), defined as RVVC patients indices (mean counts for stimulated cultures/mean counts for unwho were asymptomatic with a negative vaginal culture at the time stimulated cultures). of evaluation. Ten of the culture-positive RVVC patients were Cytokine production. Cytokine production was assessed by the tested longitudinally, during a symptomatic episode and again culture of 3 1 10 6 PBL/mL incubated in 24-well tissue culture when culture-negative. The control group consisted of healthy plates at 37ЊC with 5% CO 2 with medium alone (AIM V/glutaasymptomatic nonpregnant women between the ages of 21 and 50 mine) or additionally with 20 mg/mL PHA, 5 1 10 6 HKB/mL, with no history of vaginal candidiasis (n Å 16).
Materials and Methods
125 mg/mL SCS, or tetanus toxoid diluted 1:5 in a volume of 2 mL. The 48-h supernatants were collected, clarified, and stored at 070ЊC until use.
Specimens Collected
Blood (20-40 mL) was collected by venipuncture into heparinized tubes, a vaginal swab was collected, and a CVL was perImmunologic Assays formed with 5 mL of nonpyrogenic sterile saline. The CVL fluid was collected after 30-40 s of aspiration. No evidence of blood
The tissue culture supernatants and CVL fluid were assessed for immunoglobulins and Th1-and Th2-type cytokine expression. was present in any CVL fluid, reducing the possibility that the fluid was contaminated with systemically derived immune moleThe Th1-type cytokines included interleukin (IL)-2, interferon (IFN)-g, and IL-12. The Th2-type cytokines included IL-4, IL-5, cules. The vaginal swab was streaked onto Sabouraud dextrose agar plates and incubated at 30ЊC for 48 h. C. albicans-derived and IL-10. CVL fluid was also evaluated for immunoglobulins, including total and Candida-specific IgG, IgA, and IgE. Immune colonies were confirmed by germ tube formation in fetal bovine serum. The CVL fluid was clarified and the fluid was collected, mediators in culture supernatants were expressed as specific units of cytokine or immunoglobulin per milliliter (concentration in antifiltered through a 0.22-mm membrane, aliquoted in 0.5-mL aliquots, and frozen at 070ЊC until use. Total protein content in each gen-stimulated cultures minus that in unstimulated cultures), while mediators in CVL fluid were expressed as units of cytokine or CVL fluid sample was determined by the Lowry method with a commercial kit (Sigma, St. Louis). PBL were isolated from the immunoglobulin per milligram or microgram of protein.
IL-12 and IFN-g. IL-12 and IFN-g in the culture supernatants blood by use of ficoll-hypaque density gradient centrifugation as previously described [8] .
or lavage fluid were quantitated by a sensitive and specific com-JID 1997;176 (September) mercial ELISA (R&D Systems, Minneapolis; Genzyme, CamSigma) was added to each well in a volume of 50 mL and incubated for 1 h at room temperature. After washing four times, 50 mL of bridge, MA). The standard curve for each assay was generated in saline or AIM/glutamine medium to obtain the identical matrix of the p-nitrophenyl phosphate substrate (Sigma) was added to each well, and the reaction was allowed to develop for 20-60 min. The the lavage fluid and culture supernatants, respectively. The CVL fluids or supernatants were assayed in duplicate using 50-100 mL/ reaction was stopped with the addition of 50 mL of 3 N NaOH. Candida-specific immunoglobulin was also quantitated by ELISA by use of the same CVL fluids were quantitated by ELISA using commercial capture and biotinylated detection antibodies (Pharmingen, San Diego) and basic methodology as described above with the exception of the capture procedure and the standard. In this assay, instead of a the respective recombinant human cytokine for generation of the standard curve. The assays were performed in high protein binding capture antibody, C. albicans culture filtrate antigen (CaCF) [15] diluted to 10 mg/mL in coating buffer was used to coat the plates. EIA/A2 96-well plates (Costar) according to manufacturer's instructions. Briefly, the plates were coated with the capture antibody Since there is no commercially available Candida-specific IgG, IgA, or IgE to use as a standard, we used an approach similar to (1 mg/mL) in coating buffer (0.1 M NaHCO 3 ) and incubated overnight at 4ЊC. The plates were washed four times with PBS / 1% that described above for total IgE by use of a pooled sample of lavage fluids having absorbances above that of sterile saline. This bovine serum albumin (BSA) / 0.05% Tween 80 (wash buffer). The nonspecific binding sites were blocked with PBS / 3% BSA pooled sample was derived predominantly from RVVC patients. The sample was diluted from 1000 to 15 U/mL in sterile saline. / 0.05% Tween 80 (blocking buffer) for 3 h at room temperature. After the plate was washed several times, the standard and unPreliminary studies showed that a 1:20 dilution of lavage fluid was optimal for IgG determinations, while undiluted samples were known samples were added to each well in duplicate using a volume of 50 mL and incubated for 2 h at room temperature. After required for IgA and IgE determinations. All other aspects were identical to the detection of total immunoglobulin, with results this incubation, the plate was washed again several times, and the biotinylated detection antibody (1 mg/mL) was added to each well expressed as units of immunoglobulin per milligram of protein. and incubated for 1 h at room temperature. After several additional washings, a solution of avidin-alkaline phosphatase (diluted 1:50,000) was added, followed by addition of the substrate p-
Subjects Enrolled for Stimulation of Vaginal Anti-Candida nitrophenyl phosphate (Sigma). Quantitation of cytokines in CVL
Immunity fluid was done by use of the Ceres 900 plate reader at 405 nm as Healthy nonpregnant women between the ages of 21 and 50 described above.
without a history of RVVC were recruited. A total of 70 were Total IgG, IgA, and IgE. A sandwich ELISA was done in 96-enrolled. All participants were asked to abstain from sexual interwell EIA/A2 plates. Briefly, anti-human IgG (1 mg/mL), IgA (3 course during the testing period. Specific data on the subjects mg/mL), or IgE (10 mg/mL) antibodies (capture antibody) (Dako) enrolled were as follows: 22 (31%) were taking oral contraceptives, diluted in coating buffer (0.1 M NaHCO 3 ) was added to each well 6 (9%) were menopausal, with 2 receiving hormone replacement in a volume of 50 mL and incubated overnight at 4ЊC. On the therapy, and 2 (3%) had had hysterectomies. About 25% of the following day, the plate was washed four times with wash buffer subjects were taking minor medication or antihistamines. Thirty (PBS / 1% BSA / 0.05% Tween 80), and nonspecific binding percent of the subjects were minorities. Each subject was tested sites were blocked with 100 mL/well blocking buffer (PBS / 3% during the follicular stage of the menstrual cycle (within 2 days BSA / 0.05% Tween 80) for 2 h at room temperature. After the after the end of menses), when estradiol and progesterone are plate was washed four times, samples were added in a volume of minimal. 50 mL/well and incubated for 3 h at room temperature. Preliminary Clinical protocol. Subjects were stratified into three clinical studies revealed that CVL fluid diluted 1:20 was optimal for deprotocols. The protocols and analyses were conducted at Wayne tecting IgA and IgG, whereas undiluted samples were required for State University School of Medicine and Louisiana State UniverIgE determinations. Human IgG and IgA (Sigma) were used to sity Medical Center. In each protocol, 20 mL of blood was drawn generate standard curves for the quantitation of IgG and IgA. IgG from each participant, and a vaginal swab and CVL fluid were was serially diluted (2-fold) from 125 to 2 ng/mL. IgA was serially collected as described above. For protocol A (n Å 30), each particidiluted (2-fold) from 1000 to 15 ng/mL. Since there was no compant was given a vaginal suppository (gelatin capsule) containing mercially available human IgE at the time of this study to use as 10 8 C. albicans HKB or sterile PBS alone. For protocol B (n Å the standard, we used a pooled sample of all CVL fluids that 24), each participant was given a syringe kit prepared by a research showed positive absorbances (at least 2-fold above the mean abnurse (D. Leaman) containing 10 8 C. albicans HKB in 1.0 mL of sorbance of saline alone). The sample was serially diluted (2-fold) PBS or PBS alone. For protocol C (n Å 16), the participant was from 1000 to 15 U/mL in sterile saline and added in a volume of given the syringe kit containing soluble Candida skin test antigen 50 mL to separate wells. The blank wells contained 50 mL of sterile (Berkeley Biologicals, Berkeley, CA) diluted 1:10 in PBS or PBS saline. At the conclusion of the incubation period, the wells were alone. The commercial Candida antigen contained no adjuvants washed four times, and alkaline phosphatase-conjugated anti-human IgG (1:10,000), IgA (1:20,000), or and during an infection-free asymptomatic period of remission at a specified time for a second collection of blood (for serum (n Å 18). Ten patients were tested longitudinally both during only) and CVL fluid. In protocol A, subjects were instructed to symptomatic infection and again when asymptomatic (median return either 72 h (n Å 15) or 120 h (n Å 15) after antigen or time between testing was Ç1 -2 months). Responses by RVVC saline administration. In protocol B, subjects were instructed to patients were compared with those in control subjects with no return either 9-11 h (n Å 8), 18-20 h (n Å 8), or 30-33 h (n Å history of vaginal candidiasis (n Å 16). 8 ) after antigen or saline administration. In protocol C, the subjects were instructed to return either 16-18 h (n Å 8) or 36-40 h (n The results illustrated in figure 1 show the Th1-type cyto- of IL-2 and IFN-g were not different between controls and
The initial vaginal swab was used to identify vaginal coloniza-RVVC patients, IL-12 in CVL fluid of RVVC patients was tion by C. albicans. The blood was used for the isolation of serum significantly reduced compared with that in control subjects and PBL (initial draw only) as described above. The CVL fluid (P õ .0005).
was prepared as described above. The serum sample was used for Figure 2 illustrates the local expression of Th2-type cytoestradiol measurements to verify that subjects were tested during the follicular stage of the menstrual cycle. PBL were used in the kines (IL-4, IL-5, IL-10) for controls and patients. Although proliferation study described above with PHA and C. albicans Th2-type cytokines were also detected in CVL fluid collected HKB and SCS to verify systemic sensitization to Candida antigens. from control subjects, fewer numbers of subjects showed
The CVL fluid was used to quantitate the cytokines and immunodetectable levels than showed detectable levels of Th1-type respectively).
Cytokine and immunoglobulin determinations. These assays Evaluation of immunoglobulin levels in CVL fluid (table were done in a manner identical to that described above; PBS was 1) showed that although total IgA and IgG were reduced in used as the matrix for the standards.
Histamine. Histamine in CVL fluid was quantitated by a comsymptomatic and asymptomatic RVVC patients compared with petitive EIA kit (Immunotech International, Westbrook, ME fluid. * Significant difference (P õ .05) compared with controls.
mL; range, 0 -1041; P õ .005), but not in asymptomatic RVVC patients (median, 165 pg/mL; range, 0 -671). No difSystemic Th2-type cytokine expression had not been previously evaluated in PBL cultures for RVVC patients. Results ferences were observed between controls or RVVC patient PBL in response to C. albicans SCS, PHA, or tetanus toxoid in this study showed that while significant differences were observed, the differences were not specific to Candida anti-(data not shown).
/ 9d31$$se49
07-24-97 16:51:37 jinfa UC: J Infect gens (table 2) . For example, IL-4 was significantly increased tients in response to PHA (median, 1518 pg/mL; range, 78 -3801; vs. median, 581 pg/mL; range, 0 -2000; P õ .005; and in asymptomatic RVVC patient PBL cultures compared with controls and symptomatic RVVC patients in response to HKB median, 664 pg/mL; range, 0 -2478; P õ .004), decreased in asymptomatic RVVC patient cultures compared with controls (median, 55 pg/mL; range, 0 -252; vs. median, 20 pg/mL; range, 0 -57; P õ .01; or median, 3 pg/mL; range, 0 -12; P for responses to SCS (median, 0 pg/mL; range, 0 -347; vs. median, 460 pg/mL; range, 0 -2000; P õ .004), and decreased õ .002, respectively), SCS (median, 43 pg/mL; range, 0 -230; vs. median, 14 pg/mL; range, 0 -182; P õ .003; or in both symptomatic and asymptomatic RVVC patients compared with controls in response to tetanus toxoid (median, 38 median, 10 pg/mL; range, 0 -90; P õ .02, respectively), and tetanus toxoid (median, 56 pg/mL; range, 0 -723; vs. median, pg/mL; range, 0 -300; and median, 45 pg/mL; range, 0 -770; vs. median, 395 pg/mL; range, 0 -7834; P õ .004 and .01, 0 pg/mL; range, 0 -136; P õ .0005; or median, 0 pg/mL; range, 0 -76; P õ .0006, respectively). IL-5 was significantly respectively).
Stimulation of vaginal immunity with Candida antigen.
To decreased in symptomatic and asymptomatic RVVC patient PBL cultures compared with controls in response to HKB circumvent potential problems associated with dynamics and antigen specificity in de novo analyses of cervicovaginal secre-(median, 2.4 pg/mL; range, 0 -64; and median, 21 pg/mL; range, 0 -508; vs. median, 67 pg/mL; range, 0 -1409; P õ tions from RVVC patients, we examined the potential to stimulate local vaginal immune reactivity in vivo in normal healthy .004 and .03, respectively), SCS (median, 6 pg/mL; range, 0 -88; and median, 58 pg/mL; range, 0 -732; vs. median, 397
women without a history of vaginal candidiasis. We reasoned that since most healthy persons are sensitized to C. albicans, pg/mL; range, 0 -1363; P õ .005 and .04, respectively), and tetanus toxoid (median, 15 pg/mL; range, 0 -128; and median, it may be possible to stimulate a local immune response in women by the intravaginal introduction of C. albicans antigen. 0 pg/mL; range, 0 -211; vs. median, 90 pg/mL; range, 0 -340; P õ .013 and .026, respectively). Finally, IL-10 was Several protocols were tested covering several time intervals for immune stimulation and different Candida antigen preparasignificantly increased in asymptomatic RVVC patient PBL cultures compared with controls and symptomatic RVVC pations. Each protocol involved two CVLs for the detection of albicans challenge or in subjects given PBS (data not shown). respectively. Participants (n Å 54) were stratified into groups that received antigen (n Å 35) or saline alone (control) (n Å Constitutive expression of each immunoglobulin was, however, observed (total IgA, 100 -600 ng/mg of protein; total IgG, 30) and by time of vaginal lavage after introduction of the antigen or saline (72 or 120 h for protocol A, n Å 30; and 100 -240 ng/mg of protein; Candida-specific IgA, 350 -700 U/mg of protein; Candida-specific IgG, 600 -1500 U/mg of 9 -11, 18 -20, 30 -33 h for protocol B, n Å 24). Estradiol measurements in sera showed that all subjects were tested under protein). Total and Candida-specific IgE as well as histamine content follicular estradiol concentrations (0 -250 pg/mL). Results in all cases, however, showed no significant increases in local in the CVL fluids is illustrated in figure 5 . Constitutive expression of each immune mediator was observed before intravaginal immune reactivity after intravaginal antigen introduction (data not shown).
administration of PBS or Candida antigen. However, compared with that at time 0 for each respective group, neither total nor Protocol C involved the intravaginal introduction of C. albicans skin test antigen in a 1.0-mL volume using a syringe and Candida-specific IgE was increased in CVL fluid 16 -18 or 36 -40 h after intravaginal administration of Candida antigen transfer pipette. Participants (n Å 16) were stratified into antigen (n Å 5) or saline (n Å 3) groups and by time of vaginal or PBS. In contrast, histamine was significantly increased in CVL fluid collected 16 -18 h after challenge with Candida lavage after antigen administration (16 -18 and 36 -40 h). Median serum estradiol levels for subjects 16 -18 h after introducantigen (P õ .048) compared with that at time 0, but not in subjects given PBS or in those subjects tested 36 -40 h after tion of PBS or Candida antigen was 43 (range, 20 -159) and 69 (range, 12 -76) pg/mL, respectively. Median serum estradiol administration of Candida antigen or PBS. levels 36 -40 h after PBS or antigen administration were 189 (range, 55 -243) and 167 (range, 16 -320) pg/mL, respectively. Discussion In each of protocols A, B, and C, ú85% of the subjects tested showed positive systemic immune responses to Candida antiThis clinical study examined the vaginal presence of humoral immunity and CMI in women with RVVC and for the gen detected by at least a 2-fold increase in [ 3 H]thymidine incorporation in PBL cultured with antigen versus medium first time evaluated Th1-and Th2-type cytokines in CVL fluid and assessed the potential to stimulate putative vaginalalone (data not shown). PBL from all participants with õ2-fold increases in response to Candida antigen responded normally to associated immunity in healthy women by intravaginal challenge with Candida antigen. The presence of Th1-or Th2-PHA (ú2-fold), indicating that their PBL were capable of responding to antigenic stimuli. type cytokines in CVL fluid from RVVC patients or from normal healthy women before any exogenous antigen stimulaUnder protocol C, increases in vaginal-associated immune activity were detected following Candida antigen challenge.
tion is the first evidence of its kind suggesting that these cytokines, like immunoglobulins, are constitutively produced Figure 3 shows the median concentration (pg/mg protein) of Th1-type cytokines (IL-2, IFN-g, and IL-12) at time 0 (initial in vaginal secretions. Our data suggest that constitutive Th1-type cytokines in the vagina predominate over Th2-type cyto-CVL) and 16 -18 or 36 -40 h after intravaginal introduction of PBS or Candida antigen in separate groups of subjects.
kines. The presence of Th1-and Th2-type cytokines in CVL fluid in normal healthy women is consistent with the recent Consistent with results from the RVVC study, detectable constitutive levels of Th1-type cytokines were observed in the time report of the presence of proinflammatory cytokines (tumor necrosis factor, IL-1, and IL-6) in CVL fluid in both human 0 CVL fluid prior to intravaginal administration of antigen or PBS. Significant increases in IL-2 (P õ .047), IL-12 (P õ immunodeficiency virus -infected and noninfected women [29] . On the basis of considerable evidence in both clinical .028), and IFN-g (P õ .028) were observed between time 0 and 16 -18 h after intravaginal administration of C. albicans studies and experimental animal models suggesting a limited role for systemic immunity at the vaginal mucosa [7, 8, 17 antigen but not in subjects given PBS. In contrast to results at 16 -18 h, none of the Th1-type cytokines were increased in 19], it would seem unlikely that the constitutive cytokine production in CVL fluid was contaminated by systemically subjects whose second vaginal lavage was 36 -40 h after anti-/ 9d31$$se49 07-24-97 16:51:37 jinfa UC: J Infect derived cytokines. Furthermore, there was no evidence of periods supports cumulative data suggesting that the absence of or decrease in these two cytokines continued in the asympblood contamination in CVL fluid. The more likely explanation for the constitutive cytokine production is some level of tomatic periods of remission. A decrease in or absence of IL-12 could have important clinical implications in RVVC. IL-12 immune reactivity to normal bacterial or fungal flora.
Results for RVVC patients showed that while the majority is an important regulatory cytokine that enhances Th1-type responses and inhibits Th2-type responses [30] , influences IFNof Th1-and Th2-type cytokines in CVL fluid were unchanged in RVVC patients compared with controls, significant reducg production [31] , and enhances NK cell activity [32] . Although levels of IFN-g were low in most controls and RVVC tions in both IL-12 (Th1-type) and IL-5 (Th2-type) were observed during episodes of symptomatic vaginitis as well as patients, reduced levels of IL-12 in RVVC patients may hinder their ability to produce IFN-g during infection, which may during periods of remission. Longitudinal assessment of the 10 RVVC patients tested during symptomatic and asymptomatic ultimately affect both resistance-associated Th1-type reactivity [13, 14, 33 -35] and the induction and recruitment of NK cells into the vaginal mucosa. Similarly, low levels of IL-5 in RVVC patients would suggest a lower incidence of eosinophilia [36] in RVVC, although this contradicts a previous report showing the presence of eosinophils in vaginal smears collected from women with RVVC [22] . Systemic PBL responses from control subjects to mitogens and Candida antigens showed a mix of Th1-and Th2-type cytokines indicative of Th0-type reactivity, while responses to tetanus toxoid were dominated by Th2-type cytokines. Similar to results of our previous study [8] , Th1-type cytokines elaborated in response to Candida antigen by patient PBL were not different from controls in the majority of subjects, suggesting again that women with RVVC have normal Th1-type systemic Candida-specific CMI. The only exception was a transient decrease in IL-12 (not previously examined) in PBL from symptomatic RVVC patients stimulated with one of the two Candida antigens. Although our past studies had not assessed Th2-type cytokines in RVVC PBL cultures, the results of the present study showed both in- / 9d31$$se49 07-24-97 16:51:37 jinfa UC: J Infect creases (IL-4) and decreases (IL-5) in specific cytokine exsimilarities and differences, there were no positive correlations that would support an association or link between syspression. However, none of the systemic cytokine differences could be attributed specifically to Candida antigens. We pretemic and vaginal immune expression. As in previous reports by other laboratories, immunoglobusume that these systemic changes reflect either a true nonspecific effect or possibly inherent experimental variation, as lins measured in vaginal lavage fluid of RVVC patients showed that Candida-specific IgG and IgA concentrations were not was the overall interpretation in our previous study [8] . On the basis of the lack of a distinct pattern for the differences different from those in control subjects [20] , whereas Candidaspecific IgE was increased during symptomatic infection [21 -in the present study, we again favor the latter as the most appropriate explanation. Furthermore, while comparisons be-23]. Interestingly, total IgA and IgG were decreased in RVVC patients.
It is unclear what this may imply. Perhaps vaginal tween the vaginal expression of cytokines with those mediated by PBL in response to Candida antigens revealed both infection leads to a general reduction in nonspecific immunoglobulins. Taken together, vaginal-associated immune reactivity in women with RVVC showed no blatant deficiency or imbalance of overall Th-type cytokine expression compared with control subjects, although the decreases in IL-12 may be significant. Moreover, vaginal CMI expression showed little association with systemic Candida-specific CMI. Although we are confident in the data, caution should be taken not to overinterpret the present data, as this clinical de novo analysis contained uncontrollable limitations in experimental design. First, the dynamics and kinetics of the immune responses during infection were difficult to control, because many of the symptomatic RVVC patients attended the clinic at various times from the initiation of infection. Second, none of the differences observed in cytokine or immunoglobulin expression in the CVL fluid from RVVC patients or controls could be positively attributed to C. albicans antigen(s).
To circumvent these problems, we addressed the possibility of stimulating existing Candida-specific vaginal immunity in normal healthy women by intravaginal challenge with Candida antigen. Candida antigen was chosen instead of live organisms because of ethical considerations. All women were tested dur- ing the follicular stage of the menstrual cycle to avoid influIn contrast to the lack of local responsiveness in women given killed C. albicans, the intravaginal introduction of soluble ences of reproductive hormones during these preliminary analyses. Of the three clinical protocols tested, those involving the C. albicans skin test antigen significantly increased all three Th1-type cytokines (IL-2, IL-12, and IFN-g) in CVL fluid intravaginal introduction of C. albicans HKB did not stimulate any detectable increases in vaginal immune reactivity. On the within 16 -18 h. None of the Th2-type cytokines were significantly elevated, although amounts of IL-10 did approach sigbasis of our results using soluble Candida antigen (discussed below), we suspect that this was due to the lack of adherence nificance (P Å .07) in subjects given Candida antigen and tested at 16 -18 h. If the increase of cytokines in vaginal secreby the killed organism and subsequent inadequate contact of antigen with the mucosa. Certainly, lack of systemic sensitizations reflects the stimulation of a normal protective response in the vagina to C. albicans, our results suggest that Th1-type tion did not appear to contribute to the lack of activity, as CMI may be an integral component of this response, similar ú85% of participants showed positive PBL proliferation in to that described for animal models of mucosal and systemic response to Candida antigens.
C. albicans infections [13, 14, 33 -35] . Interestingly, subjects tested 36 -40 h after intravaginal antigen administration showed no local increase in cytokines. Assuming that a certain percentage of all subjects given Candida antigen had reactivity at 16 -18 h, these data suggest that the reactivity is transient following introduction of antigen. Alternatively, the lack of cytokine expression may have been due to the increased presence of reproductive hormones at 36 -40 h as the women approached the preovulatory stage of the menstrual cycle. There is increasing evidence that reproductive hormones negatively influence immune reactivity at both the systemic and cervicovaginal level [24, 37 -40] .
In contrast to the elevation in cytokines following intravaginal antigen administration, we were unable to detect increases in Candida-specific IgA, IgG, or IgE 16 -18 or 36 -40 h after Candida antigen challenge. These results are consistent with the lack of IL-4, which is required for IgA and IgE synthesis [41 -43] . Moreover, the lack of increased immunoglobulins may also reflect the fact that B lymphocytes are not considered resident cells of the vaginal mucosa [25] . It is possible that 
